GSK Strategy Chief: No Major M&A Likely In 2017
Executive Summary
GSK expects further consolidation among rivals in 2017 but its own focus will remain internal, as it keeps integrating assets acquired by its product swap with Novartis and as its new CEO takes corporate control.
You may also be interested in...
Out-Going GSK CEO Andrew Witty Tells Pharma To Evolve Or Die
The veteran pharma executive Andrew Witty says time – if not already gone - is running out fast for those biopharma companies who have not yet begun their necessary structural transitions.
GSK to jettison half Aspen stake to fund 'reshape'
GlaxoSmithKline plans to sell around half of its 12.4% stake in South Africa's largest listed pharma company Aspen Pharmacare – worth around $890m – through a placing to institutional investors. Having closed the landmark megadeal with Novartis last week, GSK is taking the opportunity to assess strategic options. CEO Sir Andrew Witty said ahead of the close that it would be "disingenuous" to say that the Novartis transaction did not give him "options for different structures that may enhance shareholder value."
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.